Related Experiment Video
Updated: Nov 10, 2025
Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
Published on: June 28, 2019
Therapeutic effects of coronary granulocyte colony-stimulating factor on rats with chronic ischemic heart disease
Pengcheng Ren1, Ming Zhang1, Shuren Dai1
1Department of Cardiology, Chongqing Dazu District People's Hospital, Chongqing, 402360, People's Republic of China.
Insights
Granulocyte colony-stimulating factor (G-CSF) improved cardiac function in rats with chronic ischemic heart disease (CIHD). Intracoronary G-CSF injection was safe and effective, reducing myocardial injury and promoting angiogenesis.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Hematology
Background:
- Chronic ischemic heart disease (CIHD) poses significant therapeutic challenges.
- Evaluating novel treatments for CIHD is crucial for improving patient outcomes.
Purpose of the Study:
- To assess the therapeutic efficacy of granulocyte colony-stimulating factor (G-CSF) in a rat model of CIHD.
- To compare the effects of intracoronary versus subcutaneous G-CSF administration.
Main Methods:
- A CIHD rat model was established, with rats randomized into control, subcutaneous G-CSF, and intracoronary G-CSF groups.
- Cardiac function (LVEF), myocardial injury, perfusion, and viable myocardium were assessed using angiography, dual-isotopic imaging, and MRI.
- Peripheral blood and G-CSF levels were monitored post-treatment.
Main Results:
- Both subcutaneous and intracoronary G-CSF significantly increased the peripheral blood CD34+/CD133+ cell ratio compared to controls.
- G-CSF treatment reduced distal stenosis degrees, improved LVEF, decreased infarct size, and alleviated left ventricular remodeling.
- Angiogenesis was promoted, and cardiomyocyte apoptosis was inhibited in G-CSF treated groups.
Conclusions:
- Intracoronary G-CSF injection is a safe and effective therapeutic strategy for CIHD in rats.
- G-CSF administration, particularly via intracoronary route, enhances cardiac function and promotes myocardial repair in CIHD.
- The findings support G-CSF as a potential treatment for chronic ischemic heart disease.
Background:
The aim of this study was to evaluate the therapeutic effects of coronary granulocyte colony-stimulating factor (G-CSF) on rats with chronic ischemic heart disease (CIHD).
Methods:
Thirty healthy rats were randomly divided into control, subcutaneous and intracoronary G-CSF injection groups (n = 10) after the CIHD model was established. Left ventricular ejection fraction (LVEF), myocardial injury area, myocardial perfusion area and viable myocardium were observed by coronary angiography, dual-isotopic myocardial imaging and first-pass delayed myocardial perfusion magnetic resonance imaging (MRI) before modeling as well as 2 and 4 weeks after surgery.
Results:
The peak times of peripheral blood and subcutaneous G-CSF levels were 3 and 5 days after mobilization, respectively. The peripheral blood CD34+/CD133+ cell ratio of subcutaneous or intracoronary G-CSF injection group significantly exceeded that of the control group (P < 0.05). The distal stenosis degrees of target lesions in subcutaneous and intracoronary G-CSF injection groups were significantly lower than that of the control group (P < 0.05). Compared with the situation before mobilization, LVEF was significantly improved after 2 weeks in intracoronary and subcutaneous G-CSF injection groups (P < 0.01). Their infarcted myocardial areas were reduced, the left ventricular remodeling was relieved, the percentage of viable myocardium was increased, angiogenesis was promoted and cardiomyocyte apoptosis was inhibited.
Conclusion:
Intracoronary G-CSF injection is safe and effective as subcutaneous injection, improving the cardiac function of CIHD rats.
